Typhoid Vi Polysaccharide Vaccine Market Size Forecasted To Achieve $13.36 Billion By 2029 With Steady Growth

The Typhoid Vi Polysaccharide Vaccine Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Typhoid Vi Polysaccharide Vaccine Market Size and Projected Growth Rate?
The market size for the typhoid vi polysaccharide vaccine has seen a quick expansion in the past few years. The market is projected to escalate from $5.78 billion in 2024 to about $6.77 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 17.1%. This surge in the historic span can be credited to factors like the widespread occurrence of the disease, global health campaigns, vaccinations for travelers, government-backed immunization drives, and the efficiency and safety of the vaccine.

In the coming years, the market for the typhoid vi polysaccharide vaccine is set to experience a swift expansion. It is projected to reach $13.36 billion by 2029, with a compound annual growth rate (CAGR) of 18.5%. The growth predicted for this period can be attributed to a combination of factors such as wider immunization schemes, a global focus on health policies, epidemiological surveillance, increased demand in the field of travel medicine, and various environmental and social aspects. Key trends for this forecast period include investments in research and development, regulatory backing, epidemiological research, and increased public health awareness.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313

What Are the Major Segments in the Typhoid Vi Polysaccharide Vaccine Market?
The typhoid vi polysaccharide vaccine market covered in this report is segmented -

1) By Type: Child, Adult
2) By Route Of Administration: Oral, Parenteral
3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:
1) By Child: Pediatric Formulations, Age-Specific Dosages
2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

What Are The Driving Typhoid Vi Polysaccharide Vaccine Market Evolution?
The escalating incidence of typhoid is projected to spur the expansion of the typhoid VI polysaccharide vaccine market. Typhoid, a potentially deadly infection caused by Salmonella typhi bacteria, typically propagates via tainted food or beverages. Typhoid Vi polysaccharide vaccine is employed to protect both adults and children older than 2 from typhoid fever instigated by Salmonella enterica serovar Typhi, or S. Typhi. As an example, data from the UK Health Security Agency, a governmental organization in the UK, revealed in August 2024 that laboratory-confirmed symptomatic instances of enteric fever in England, Wales, and Northern Ireland saw an uptick from 2021 to 2022, with S. Typhi cases climbing from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Consequently, the increasing prevalence of typhoid is fuelling the growth of the typhoid Vi polysaccharide vaccine market.

Which Firms Dominate The Typhoid Vi Polysaccharide Vaccine Market Segments?
Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

What Trends Are Expected to Dominate the Typhoid Vi Polysaccharide Vaccine Market in the Next 5 Years?
Forming strategic alliances has become a prominent trend in the typhoid Vi polysaccharide vaccine industry. Major corporations in this sector are establishing partnerships to fortify their stand in the typhoid Vi polysaccharide vaccine market. For instance, in July 2022, The International Vaccine Institute, an organization based in South Korea that focuses on worldwide infectious diseases like cholera, typhoid, shigella, and salmonella, collaborated with Moderna, a biopharmaceutical company from the U.S. As a result of this collaboration, the world witnessed its first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Which Is The Largest Region In The Typhoid Vi Polysaccharide Vaccine Market?
Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Typhoid Vi Polysaccharide Vaccine Market?
2. What is the CAGR expected in the Typhoid Vi Polysaccharide Vaccine Market?
3. What Are the Key Innovations Transforming the Typhoid Vi Polysaccharide Vaccine Industry?
4. Which Region Is Leading the Typhoid Vi Polysaccharide Vaccine Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.